| 1400 |
National Cancer Institute |
Html |
en |
Pruritus (PDQ®)–Patient Version |
Expert-reviewed information summary about pruritus (itching of the skin) as a complication of cancer or its treatment. Approaches to the management and treatment of pruritus are discussed. |
| pruritus | 0.90328 |
| cancer treatment | 0.548786 |
| pruritus triggers | 0.621529 |
| itchy area | 0.539512 |
| PDQ cancer information | 0.801119 |
| sensitive skin | 0.546664 |
| clinical trials | 0.578 |
| slightly warm water | 0.581894 |
| skin irritation | 0.524209 |
| cancer information summary | 0.687111 |
| clinical trial | 0.527617 |
| breast cancer prevention | 0.527738 |
| allergic skin reactions | 0.565555 |
| PDQ summaries | 0.536776 |
| NCI’s PDQ | 0.543089 |
| NCI PDQ cancer | 0.611108 |
| abnormally dry skin | 0.57148 |
| radiation therapy | 0.699633 |
| mild skin cleansers | 0.572586 |
| healthy skin | 0.527165 |
| dry skin | 0.774485 |
| severe pruritus | 0.605619 |
| treatment | 0.566915 |
| skin reactions | 0.571172 |
|
| cancer prevention | 0.529379 |
| skin | 0.938312 |
| fabric softener | 0.603284 |
| Cancer Information Service | 0.550768 |
| PDQ Supportive | 0.525373 |
| Skin care | 0.536556 |
| treatment clinical trials | 0.52545 |
| National Cancer Institute | 0.683212 |
| PDQ documents | 0.525692 |
| pruritus feels | 0.65464 |
| Palliative Care Editorial | 0.58903 |
| new treatment | 0.528187 |
| Long-term dry skin | 0.58669 |
| Cancer Care page | 0.536284 |
| PDQ database | 0.530553 |
| Care Editorial Board | 0.591687 |
| skin stay | 0.527676 |
| PDQ summary | 0.56881 |
| skin biopsy | 0.53042 |
| sedimentation rate | 0.58564 |
| skin cells | 0.531813 |
| skin lesions | 0.545694 |
| cancer information summaries | 0.561413 |
| comprehensive cancer information | 0.556845 |
|
CLICK HERE |
| 1573 |
National Cancer Institute |
Html |
en |
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of paranasal sinus and nasal cavity cancer. |
| clinical trial | 0.388177 |
| treatment | 0.382326 |
| nasal cavity cancer | 0.775733 |
| nasal cavity | 0.985485 |
|
| radiation therapy | 0.64284 |
| cancer | 0.858763 |
| paranasal sinus | 0.474859 |
| clinical trials | 0.346263 |
|
CLICK HERE |
| 1600 |
National Cancer Institute |
Html |
en |
Nutrition in Cancer Care (PDQ®)–Patient Version |
Expert-reviewed information summary about the causes and management of nutritional problems that occur in patients with cancer. |
| cancer treatment | 0.815724 |
| foods | 0.591336 |
| body | 0.50774 |
| PDQ cancer information | 0.539768 |
| general health | 0.483553 |
| mouth sores | 0.564301 |
| nutrition problems | 0.511061 |
| cancer information summary | 0.514016 |
| Cancer Care section | 0.490312 |
| enteral nutrition | 0.493173 |
| cancer care | 0.499373 |
| cancer patients | 0.772982 |
| weight loss | 0.581589 |
| dry mouth | 0.559356 |
| NCI PDQ cancer | 0.489458 |
| nutrition | 0.675709 |
| effects | 0.559624 |
| good nutrition | 0.476052 |
| nutrition therapy | 0.671346 |
| radiation therapy | 0.583611 |
| Advanced Cancer section | 0.512145 |
| nutrition support care | 0.489001 |
| cancer treatments | 0.531014 |
| parenteral nutrition support | 0.491942 |
| cancer prevention | 0.486895 |
|
| cancer cells | 0.480334 |
| Cancer Information Service | 0.511605 |
| palliative care | 0.476957 |
| nutrients | 0.514961 |
| certain foods | 0.495203 |
| parenteral nutrition | 0.492581 |
| National Cancer Institute | 0.539267 |
| advanced cancer | 0.530168 |
| white blood cell | 0.522179 |
| fight infection | 0.479873 |
| low white blood | 0.494372 |
| breast cancer | 0.518198 |
| cancer patients control | 0.508745 |
| health | 0.485589 |
| food | 0.567108 |
| PDQ summary | 0.508916 |
| Eat foods | 0.503278 |
| following nutrition problems | 0.482655 |
| mouth | 0.591038 |
| cancer information summaries | 0.483904 |
| comprehensive cancer information | 0.47883 |
| cancer | 0.980934 |
| information | 0.558957 |
| Cancer survivors | 0.484253 |
|
CLICK HERE |
| 1729 |
National Cancer Institute |
Html |
en |
Hyperthermia in Cancer Treatment |
A fact sheet that defines hyperthermia (treating tumors with heat) and its side effects. |
| cancer treatment | 0.403898 |
| peritoneal cavity temperature | 0.426528 |
| External applicators | 0.382217 |
| whole-body hyperthermia | 0.729094 |
| van der Zee | 0.371709 |
| Clinical Radiation Oncology. | 0.380706 |
| tumor location | 0.365525 |
| regional hyperthermia | 0.5725 |
| hyperthermic peritoneal perfusion | 0.490656 |
| metastatic cancer | 0.36336 |
| Gibbs FA Jr | 0.369277 |
| normal tissues | 0.422996 |
| cancer therapy | 0.407309 |
| hyperthermia treatment | 0.61506 |
| bladder cancer | 0.363102 |
| Deep tissue approaches | 0.386891 |
| clinical trials | 0.532546 |
| DeVita VT Jr. | 0.371357 |
| interstitial hyperthermia | 0.571391 |
| hyperthermia | 0.901227 |
| tissue characteristics | 0.386571 |
| hot water blankets | 0.375371 |
| peritoneal cavity | 0.431179 |
| hyperthermia techniques | 0.560349 |
| radiation therapy | 0.457463 |
|
| high temperatures | 0.42664 |
| primary peritoneal mesothelioma | 0.407141 |
| local hyperthermia | 0.597761 |
| body cavity | 0.386007 |
| cancer cells | 0.536875 |
| anticancer drugs | 0.424955 |
| Cancer Information Service | 0.393124 |
| Libutti SK | 0.372166 |
| tumor size | 0.36657 |
| certain anticancer drugs | 0.383187 |
| B.C. Decker Inc. | 0.373174 |
| Samulski TV. Hyperthermia | 0.573888 |
| Numerous clinical trials | 0.395138 |
| Clinical Trials Information | 0.383207 |
| malignant peritoneal mesothelioma | 0.399886 |
| body tissue | 0.392759 |
| Regional perfusion techniques | 0.40208 |
| Bast RC Jr. | 0.371129 |
| stomach cancer | 0.363295 |
| tumor | 0.394758 |
| inserts small needles | 0.373242 |
| et al | 0.437187 |
| higher temperatures | 0.384967 |
| research studies | 0.385011 |
|
CLICK HERE |
| 1739 |
National Cancer Institute |
Html |
en |
Paget Disease of the Breast |
A fact sheet about Paget disease of the breast, a rare type of cancer that is sometimes called Paget disease of the nipple or mammary Paget disease. |
| widely accepted theory | 0.431005 |
| Paget disease | 0.968679 |
| lymph node dissection | 0.448538 |
| breast travel | 0.50595 |
| Female Breast | 0.492116 |
| benign skin conditions | 0.467839 |
| invasive cancer | 0.46682 |
| Breast Cancer Research | 0.515399 |
| nearby lymph nodes | 0.47834 |
| 5-year relative survival | 0.483297 |
| circular cutting tool | 0.430646 |
| lymph node biopsy | 0.495901 |
| sentinel lymph node | 0.515084 |
| areola | 0.440286 |
| entire nipple | 0.437315 |
| additional diagnostic tests | 0.431017 |
| Paget cells | 0.564932 |
| breast tumor | 0.509157 |
| lymph nodes | 0.480504 |
| nipple biopsy | 0.469807 |
| lymph node surgery | 0.448775 |
| invasive breast cancer | 0.541802 |
| breast lump | 0.501651 |
| extramammary Paget disease | 0.567848 |
| magnetic resonance imaging | 0.430693 |
|
| cancer cells | 0.444445 |
| breast cancer recurrence | 0.516664 |
| benign skin condition | 0.434676 |
| National Cancer Institute | 0.437477 |
| tumor cells | 0.436713 |
| early symptoms | 0.436544 |
| rare type | 0.434028 |
| breast changes | 0.501251 |
| breast tumors | 0.519719 |
| British doctor Sir | 0.43376 |
| Breast Journal | 0.497022 |
| clinical breast exam | 0.531889 |
| breast cancer | 0.589051 |
| HER2 protein overexpression | 0.430335 |
| Sir James Paget | 0.592188 |
| people | 0.452202 |
| breast cancer treatments | 0.51665 |
| lymph node involvement | 0.446932 |
| darker circle | 0.435564 |
| axillary lymph node | 0.477668 |
| mammary Paget disease | 0.579396 |
| et al | 0.471939 |
| breast | 0.816594 |
| Surgical Oncology | 0.430364 |
|
CLICK HERE |
| 1920 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de vejiga (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de vejiga. |
| pequeño bucle | 0.447801 |
| siguientes procedimientos | 0.673413 |
| Schistosoma haematobium | 0.482783 |
| cistectomÃa segmentaria | 0.460288 |
| estadio iv | 0.822603 |
| cáncer.ampliar cistoscopia | 0.483661 |
| pequeña cantidad | 0.462732 |
| estadio ii | 0.569624 |
| túbulos renales | 0.485429 |
| siguientes tipos | 0.465952 |
| rayos x | 0.462117 |
| sistema urinario masculino | 0.534793 |
| enlace drugs approved | 0.625136 |
| células t | 0.506117 |
| posibles signos | 0.638701 |
| National Cancer Institute | 0.427365 |
|
| pelvis renal | 0.667965 |
| Instituto Nacional | 0.454933 |
| PDQ Tratamiento | 0.458142 |
| antecedentes familiares | 0.468632 |
| Physician Data Query | 0.515351 |
| Bladder Cancer | 0.523198 |
| estadio iii | 0.506874 |
| siguientes situaciones | 0.472048 |
| vejiga almacena | 0.929353 |
| pequeños hongos | 0.45501 |
| panel derecho | 0.577787 |
| células renales | 0.591906 |
| siguientes sumarios | 0.537471 |
| siguientes pruebas | 0.493409 |
| siguientes estadios | 0.478175 |
|
CLICK HERE |
| 1945 |
National Cancer Institute |
Html |
es |
Efectos tardíos del tratamiento anticanceroso en la niñez (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de los problemas de salud que aparecen una vez que termina el tratamiento del cáncer. |
| cancer statistics | 0.312893 |
| among adult survivors | 0.309342 |
| health insurance | 0.30576 |
| childhood leukemia survivors | 0.314627 |
| Marrow Transplant Survivor | 0.306695 |
| largo plazo | 0.353459 |
| Cancer Survivor cohort | 0.310798 |
| CA Cancer | 0.308516 |
| group long-term follow-up | 0.307764 |
| mortality among 5-year | 0.309974 |
| health conditions | 0.3067 |
| young adult cancers | 0.387348 |
| late mortality | 0.309117 |
| Ness KK | 0.312945 |
| among childhood cancer | 0.329959 |
| adult survivors | 0.341543 |
| Hudson MM | 0.322937 |
| among survivors | 0.313213 |
| British Childhood Cancer | 0.315849 |
| utilization among long-term | 0.306183 |
| childhood cancer | 0.973475 |
| cancer survivor study | 0.608871 |
| late effects | 0.312383 |
| SEER Cancer Statistics | 0.308306 |
| long-term survivors | 0.338777 |
|
| health care utilization | 0.307102 |
| Survivor Study cohort | 0.310239 |
| chronic health conditions | 0.305835 |
| among adolescent survivors | 0.308292 |
| Care Cancer | 0.309376 |
| among 5-year survivors | 0.328567 |
| Pediatr Blood Cancer | 0.42011 |
| oncology group long-term | 0.310223 |
| adolescent cancers | 0.313982 |
| efectos tardÃos | 0.375703 |
| survivors research program | 0.306998 |
| report from | 0.396085 |
| National Cancer Institute | 0.308232 |
| Oeffinger KC | 0.306859 |
| health care | 0.314251 |
| mortality among survivors | 0.308816 |
| Clin Oncol | 0.375569 |
| childhood cancer survivor | 0.872407 |
| medical care | 0.307228 |
| among long-term survivors | 0.315379 |
| late mortality among | 0.306982 |
| long-term follow-up guidelines | 0.320022 |
| Outcomes Among Childhood | 0.309917 |
| children's oncology group | 0.433388 |
|
CLICK HERE |
| 3769 |
National Cancer Institute |
Html |
es |
Medicina de precisión en el tratamiento del cáncer |
Información sobre el papel que tiene la medicina de precisión en el tratamiento del cáncer. |
| precisión para tratamiento | 0.796037 |
| máquina llamada secuenciador | 0.682468 |
| cuáles cambios | 0.881741 |
| cuáles tratamientos funcionarán | 0.880419 |
| que los pacientes | 0.633734 |
|
| campo de investigación | 0.604701 |
| seguro médico | 0.550546 |
| cáncer el cambio | 0.9829 |
| responda el tumor | 0.621072 |
| a cuáles tratamientos | 0.724195 |
|
CLICK HERE |
| 3876 |
National Cancer Institute |
Html |
en |
The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) |
Apply for the NCI F99/K00 Award that helps late-stage doctoral candidates finish their training and then transition into cancer-focused research positions. |
| K00 phase institution | 0.388613 |
| applicant institution | 0.265884 |
| Research Doctoral candidates | 0.275389 |
| Funding Opportunity Announcement | 0.903132 |
| research supplies | 0.244496 |
| Career Development Award | 0.350987 |
| k00 award | 0.331719 |
| Ph.D. dissertation requirements | 0.237088 |
| phase institutional representative | 0.335728 |
| project award period | 0.253621 |
| indirect costs | 0.425626 |
| NCI F99/K00 Predoc | 0.307817 |
| Institutional Allowance | 0.281782 |
| Career Development Support | 0.249362 |
| Research Career Development | 0.347168 |
| k00 phase | 0.762118 |
| Research Plan section | 0.261319 |
| career development skills | 0.241364 |
| health-related Ph.D. program | 0.243519 |
| F99 primary sponsor | 0.23706 |
| Research Service Award | 0.312163 |
| Individual Research Career | 0.265006 |
| mandatory NCI-sponsored conference | 0.307767 |
| Opportunity Announcement instructions | 0.260896 |
| career development research | 0.317687 |
|
| dissertation research project | 0.396866 |
| Ph.D. degree program | 0.256222 |
| valid U.S. visas | 0.237157 |
| Postdoctoral Fellow Transition | 0.248842 |
| Application Guide | 0.311615 |
| NCI Predoctoral | 0.237727 |
| F99 phase | 0.471921 |
| dissertation research training | 0.299174 |
| program staff | 0.238571 |
| Program Staff Contact | 0.236142 |
| Research Strategy | 0.247855 |
| F99/K00 Award | 0.359733 |
| F99 grant mechanism | 0.235643 |
| assigned NCI Program | 0.270275 |
| Development Award Supplemental | 0.254853 |
| F99 award | 0.269956 |
| fringe benefits | 0.272186 |
| valid U.S. visa | 0.254123 |
| career development | 0.562023 |
| Research Plan Sections | 0.252481 |
| Fellowship Applicant Section | 0.257658 |
| F99/K00 Award application | 0.300758 |
| health-related research field | 0.279872 |
| Postdoctoral Research Direction | 0.273719 |
|
CLICK HERE |
| 15846 |
National Cancer Institute |
Html |
en |
RAS Biochemistry and Biophysics |
This RAS Biochemistry and Biophysics lab investigates signaling by RAS proteins, which is regulated by the interactions with substrates, protein partners, and membranes. |
| cell membranes | 0.473685 |
| Nuclear Magnetic Resonance | 0.585708 |
| Biophysics Group team | 0.636374 |
| mutant RAS | 0.650163 |
| KRAS proteins | 0.677168 |
| nanodiscs | 0.374828 |
| cancer deaths | 0.469996 |
| fully modified KRAS | 0.804703 |
| different cancers | 0.503399 |
| Washington University | 0.469252 |
| analytical ultracentrifugation | 0.487353 |
| protein-nanodisc complexes | 0.475228 |
| atomic levels | 0.48075 |
| stephena@mail.nih.gov | 0.45777 |
| Ridge National Laboratory | 0.591017 |
| Rodolfo Ghirlando | 0.472711 |
| artificial lipid bilayers | 0.682865 |
| KRAS4b protein | 0.638588 |
| sensitive techniques | 0.481762 |
| Carla Mattos | 0.458864 |
| California | 0.350663 |
| Northeastern University | 0.475122 |
| RAS proteins | 0.703869 |
| neutron scattering | 0.468073 |
| RAS Biochemistry | 0.737959 |
|
| different KRAS | 0.64483 |
| different lipid compositions | 0.713219 |
| Chris Stanley | 0.450409 |
| fully modified KRAS4b | 0.914598 |
| Jay Groves | 0.463932 |
| interactions | 0.440981 |
| intrinsic hydrolysis rates | 0.625326 |
| numerous interacting partner | 0.64654 |
| inner plasma membrane | 0.635847 |
| Marco Tonelli | 0.478206 |
| surrogate | 0.33572 |
| St. Louis | 0.448878 |
| Digestive Kidney Dieases | 0.603479 |
| National Institute | 0.589812 |
| Paul Henderson | 0.462542 |
| single molecule analysis | 0.605131 |
| different mutant proteins | 0.699255 |
| dozen different mutants | 0.686498 |
| biophysical assays | 0.484191 |
| binding affinities | 0.477155 |
| Steve Sligar | 0.461855 |
| biophysics group | 0.812528 |
| major oncogenic mutants | 0.687098 |
| KRAS account | 0.631848 |
|
CLICK HERE |